In addition, Moody’s affirmed the “A1” rating on Aspirus’ series 2015A, series 2013, series 2004 and series 1998B bonds, affecting a total of $164 million of debt.
The assignment and affirmation are a result of several factors, including Aspirus’ solid operating performance, favorable balance sheet metrics and modest leverage. Moody’s also acknowledged Apirus’ highly competitive market, small size and upcoming capital spending.
The outlook is stable, reflecting Moody’s expectation that Aspirus will maintain its operating performance and favorable liquidity metrics through the upcoming period of high capital spending.
More articles on healthcare finance:
U of Mass Medical School founds Institute for Rare Diseases Research with $10M gift from Chinese businessman
Long-term funding uncertain for teaching health centers in underserved areas: 5 things to know
Donations to help foot part of uninsured shooting victims’ hospital bills, Las Vegas hospital says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
